James A. Sloand

B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab

R. John Looney, Jennifer H. Anolik, Debbie Campbell et al. · Arthritis & Rheumatism · 2004 · 772 citations

Randomized, Double-Blind Trial of Antibiotic Exit Site Cream for Prevention of Exit Site Infection in Peritoneal Dialysis Patients

Judith Bernardini, Filitsa Bender, Tracey Florio et al. · Journal of the American Society of Nephrology · 2005 · 247 citations

Urology, Antimicrobial Susceptibility, Exit Site Infection +15

A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome

James A. Sloand, Mark Shelly, Andrew Feigin et al. · American Journal of Kidney Diseases · 2004 · 206 citations

Restless Legs, Placebo-controlled Trial, Rehabilitation +2

Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop

Allison Tong, Braden Manns, Angela Yee‐Moon Wang et al. · Kidney International · 2018 · 193 citations · Full text

Urology, Renal Disease, Health Policy +9

Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis

Ravindra L. Mehta, Glynis Scott, James A. Sloand et al. · The American Journal of Medicine · 1990 · 190 citations